Hepatic Leptin Action and Leptin Resistance
肝脏瘦素作用和瘦素抵抗
基本信息
- 批准号:7142795
- 负责人:
- 金额:$ 28.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-08-01 至 2010-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The actions of the adipocyte-derived hormone leptin on lipid metabolism are proposed to be important in preventing the development of tissue lipotoxicity and lipid-related insulin resistance. This is best illustrated in leptin-deficient states, where the administration of exogenous leptin corrects systemic dyslipidemia, excessive storage of lipid in peripheral tissues such as the liver, and insulin resistance associated with this condition. Furthermore, states of leptin resistance such as human obesity and diet-induced obesity (DIO) are characterized by a similar metabolic phenotype to leptin deficient conditions, implicating a role for a loss of leptin action in the pathogenesis of the metabolic abnormalities of obesity. However, despite some progress, our understanding of the mechanisms of leptin regulation of lipid metabolism and insulin action, and the mechanisms of leptin resistance remains poor. Our recent work has focused on the effects and mechanisms of leptin action on lipid metabolism .in liver, a central organ in the regulation of whole-body lipid homeostasis. In brief these studies established a novel role for leptin in the acute regulation of hepatic lipid levels, an effect that is impaired in obesity, and identified a biochemical mechanism for this defect. Specifically, we have demonstrated (i) that leptin rapidly (within approximately 100 min) decreases liver triglyceride levels; (ii) that DIO induces resistance to the acute triglyceride-lowering effects of leptin; (iii) that activation of liver PI3-kinase is required for the effects of leptin on hepatic triglyceride levels, and (iv) that defective leptin activation of liver PI3-kinase is a novel mechanism of leptin resistance in obesity. The central objective of the current proposal is to extend these studies to determine (i) the lipid metabolic pathways in liver acutely regulated by leptin; (ii) the biochemical/molecular mechanisms of leptin action on hepatic lipid metabolism; (iii) the interactions of insulin and leptin on hepatic metabolism, and (iv) the biochemical mechanisms of hepatic leptin resistance in obesity. In undertaking these studies, we will increase our understanding of the mechanisms of leptin action and the contribution of leptin resistance to the metabolic abnormalities of obesity.
描述(由申请人提供):脂肪细胞衍生激素瘦素对脂质代谢的作用被认为在预防组织脂毒性和脂质相关胰岛素抵抗的发展中是重要的。这在瘦素缺乏状态中得到最好的说明,其中外源性瘦素的施用纠正了全身性血脂异常、脂质在外周组织如肝脏中的过度储存以及与这种状况相关的胰岛素抵抗。此外,瘦素抵抗状态如人肥胖和饮食诱导的肥胖(DIO)的特征在于与瘦素缺乏病症相似的代谢表型,暗示瘦素作用丧失在肥胖代谢异常的发病机制中的作用。然而,尽管取得了一些进展,我们对瘦素调节脂质代谢和胰岛素作用的机制以及瘦素抵抗的机制的理解仍然很差。近年来,我们的研究主要集中在瘦素对肝脏脂质代谢的影响及其机制。简而言之,这些研究确立了瘦素在肝脏脂质水平的急性调节中的新作用,这种作用在肥胖症中受损,并确定了这种缺陷的生化机制。具体来说,我们已经证明(i)瘦素迅速(ii)DIO诱导对瘦素的急性甘油三酯降低作用的抵抗;(iii)肝PI 3-激酶的活化是瘦素对肝甘油三酯水平的影响所必需的,和(iv)肝脏PI 3-激酶的缺陷性瘦素激活是肥胖症中瘦素抵抗的新机制。目前建议的中心目标是扩展这些研究,以确定(i)肝脏中的脂质代谢途径,瘦素急性调节;(ii)的生化/分子机制瘦素对肝脏脂质代谢的作用;(iii)胰岛素和瘦素对肝脏代谢的相互作用,和(iv)肥胖症的肝脏瘦素抵抗的生化机制。通过这些研究,我们将加深对瘦素作用机制以及瘦素抵抗对肥胖代谢异常的作用的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT M O'DOHERTY其他文献
ROBERT M O'DOHERTY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT M O'DOHERTY', 18)}}的其他基金
相似国自然基金
KCTD10对2型免疫反应(Th2)的调控研究
- 批准号:2020JJ4441
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
乙烯合酶ACS家族的AEF蛋白调节拟南芥开花时间的机制研究
- 批准号:31970735
- 批准年份:2019
- 资助金额:58.0 万元
- 项目类别:面上项目
USP13调控IL-18诱导的NF-κB活化的分子机制研究
- 批准号:31900556
- 批准年份:2019
- 资助金额:26.0 万元
- 项目类别:青年科学基金项目
let-7通过SOCS1调控巨噬细胞极化及其在前列腺癌进展中的作用
- 批准号:81560465
- 批准年份:2015
- 资助金额:38.0 万元
- 项目类别:地区科学基金项目
纳米微粒载NF-κB圈套基因对神经发育缺陷大鼠模型的干预研究
- 批准号:30870892
- 批准年份:2008
- 资助金额:8.0 万元
- 项目类别:面上项目
相似海外基金
Longitudinal Modeling of Pro-Inflammatory Cytokines, Hazardous Alcohol Use, and Cerebral Metabolites as Predictors of Neurocognitive Change in People with HIV
促炎细胞因子、有害酒精使用和脑代谢物的纵向建模作为 HIV 感染者神经认知变化的预测因子
- 批准号:
10838849 - 财政年份:2024
- 资助金额:
$ 28.96万 - 项目类别:
Role of Frizzled 5 in NK cell development and antiviral host immunity
Frizzled 5 在 NK 细胞发育和抗病毒宿主免疫中的作用
- 批准号:
10748776 - 财政年份:2024
- 资助金额:
$ 28.96万 - 项目类别:
Strategies for next-generation flavivirus vaccine development
下一代黄病毒疫苗开发策略
- 批准号:
10751480 - 财政年份:2024
- 资助金额:
$ 28.96万 - 项目类别:
Development of platform for non-invasive, rapid, and simple analysis of cytokine secretion from single cells
开发非侵入、快速、简单分析单细胞细胞因子分泌的平台
- 批准号:
23H01824 - 财政年份:2023
- 资助金额:
$ 28.96万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Therapeutic approach to confer an anti-tumorigenic role of IL-6 to the pro-tumorigenic cytokine in effector T cells
赋予效应T细胞中促肿瘤细胞因子IL-6抗肿瘤作用的治疗方法
- 批准号:
23K06723 - 财政年份:2023
- 资助金额:
$ 28.96万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Diversity of haematopoietic cytokine receptor activation exploring with marine probes
用海洋探针探索造血细胞因子受体激活的多样性
- 批准号:
23K14019 - 财政年份:2023
- 资助金额:
$ 28.96万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Bio-Responsive and Immune Protein-Based Therapies for Inhibition of Proteolytic Enzymes in Dental Tissues
用于抑制牙齿组织中蛋白水解酶的基于生物响应和免疫蛋白的疗法
- 批准号:
10555093 - 财政年份:2023
- 资助金额:
$ 28.96万 - 项目类别:
Maternal immune activation remodeling of offspring glycosaminoglycan sulfation patterns during neurodevelopment
神经发育过程中后代糖胺聚糖硫酸化模式的母体免疫激活重塑
- 批准号:
10508305 - 财政年份:2023
- 资助金额:
$ 28.96万 - 项目类别:
Engineering T cells to overcome inhibitory receptor signals that limit the efficacy of adoptive cell therapy against ovarian cancer
改造 T 细胞以克服抑制性受体信号,这些信号限制了过继性细胞疗法对卵巢癌的疗效
- 批准号:
10526155 - 财政年份:2023
- 资助金额:
$ 28.96万 - 项目类别:














{{item.name}}会员




